Hemolytic disease of the newborn medical therapy
|
Hemolytic disease of the newborn Microchapters |
|
Differentiating Hemolytic disease of the newborn from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic disease of the newborn medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemolytic disease of the newborn medical therapy |
|
Hemolytic disease of the newborn medical therapy in the news |
|
Directions to Hospitals Treating Hemolytic disease of the newborn |
|
Risk calculators and risk factors for Hemolytic disease of the newborn medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Before birth, options for treatment include intrauterine transfusion or early induction of labor when pulmonary maturity has been attained, fetal distress is present, or 35 to 37 weeks of gestation have passed. The mother may also undergo plasma exchange to reduce the circulating levels of antibody by as much as 75%.
After birth, treatment depends on the severity of the condition, but could include temperature stabilization and monitoring, phototherapy, transfusion with compatible packed red blood, exchange transfusion with a blood type compatible with both the infant and the mother, sodium bicarbonate for correction of acidosis and/or assisted ventilation.
Rhesus-negative mothers who have had a pregnancy with/are pregnant with a rhesus-positive infant are given Rh immune globulin (RhIG) at 28 weeks during pregnancy and within 72 hours after delivery to prevent sensitization to the D antigen. It works by binding any fetal red cells with the D antigen before the mother is able to produce an immune response and form anti-D IgG. A drawback to pre-partum administration of RhIG is that it causes a positive antibody screen when the mother is tested which is indistinguishable from immune reasons for antibody production.